{"nctId":"NCT03020082","briefTitle":"Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III","startDateStruct":{"date":"2016-06"},"conditions":["Chronic Hepatitis C"],"count":141,"armGroups":[{"label":"Danoprevir, Ritonavir, Peg-IFN,RBV","type":"EXPERIMENTAL","interventionNames":["Drug: Danoprevir","Drug: Ritonavir","Drug: peginterferon alfa-2a","Drug: RBV"]}],"interventions":[{"name":"Danoprevir","otherNames":["ASC08"]},{"name":"Ritonavir","otherNames":[]},{"name":"peginterferon alfa-2a","otherNames":["Peg-IFN"]},{"name":"RBV","otherNames":["Ribasphere®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* Chronic HCV infection (≥ 6 months)\n* Serum HCV RNA of ≥ 1 × 104 IU/mL are documented\n* Hepatitis C virus GT1\n* Never received prior-treatment for HCV with interferon, RBV, or other direct-acting or host-targeting antivirals for HCV\n* Non-cirrhosis patients: Non-cirrhosis is defined (1)Fibroscan defined as: ˂ 14.6 kPa during screening period, or liver biopsy determined 1 year before recruiting (Metavir score ˂ 3);(2) during screening period 9.6\\<Fibroscan indicator ≤12.9, liver biopsy need to confirm non-cirrhosis.\n* Others as specified in the detailed protocol\n\nExclusion Criteria:\n\n* Patients with Fibroscan detection value \\> 12.9 kPa, or histologic examination for liver cirrhosis patients\n* Presence or history of non-hepatitis C chronic liver disease (e.g. HH, AIH, Wilson's disease, α1 antitrypsin deficiency, drug- or toxin-induced liver disease)\n* History of liver cell cancer, or suspected hepatocellular carcinoma (HCC) patients before or during screening , or imaging studies found suspicious nodules, or AFP \\> 50 ng/mL\n* Positive hepatitis A antibody，positive hepatitis B surface antigen，HIV antibody\n* Presence or history of nervous system diseases and/or mental illness, inability to control oneself or express oneself.\n* Patients with obvious cardiovascular dysfunction\n* Pregnant or nursing female, nor unwilling to take reliable contraception\n* Others as specified in the detailed protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":141},"commonTop":["Anemia","Fever"]}}}